Safety and efficacy of favipiravir and camostat mesilate in patients with COVID-19.

A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir and camostat mesilate in patients with COVID-19.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200436

Enrollment

200

Registered

2021-03-23

Start date

2021-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Coronavirus

Interventions

oral administration of favipiravir, favipiravir plus camostat mesilate, or neither favipiravir nor camostat mesilate in patients with COVID-19.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) SARS-CoV-2 test positive 2) diagnosed with COVID-19 3) fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan 4) hospital admission 6) patients who have given written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1) pregnancy 2) lactation 3) Women who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 14 days after the end of its administration. Men or their partners who are not able to give informed consent regarding contraception and using contraceptive divices from the initiation of favipiravir to 10 days after the end of its administration.

Design outcomes

Primary

Measure	Time frame
expected proportion and 95% CI of SARS-CoV-2 disappearance on the 10th day after starting the treatment.	—

Secondary

Measure	Time frame
expected value and 95% CI of ratio of C-reactive protein before versus on the 10th day after starting the treatment.	—

Contacts

Public ContactTetsuya Nakamura

Gunma Universty Hospital

nakamurt@gunma-u.ac.jp+81-27-220-8740

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026